BVS vs MRK: fair value comparison
Bioventus Inc. and Merck & Co., Inc. · Updated 2026-09-13
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, BVS currently sits closer to the top of our discount ranking.
| BVS | MRK | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $13.67 | $143.93 |
| 12-month range | $6.56–$13.67 | $80.60–$149.86 |
| Sector rank | #89 of 113 Healthcare | #94 of 113 Healthcare |
| Quality grade | C | C |
| Leverage | Moderate | Moderate |
| Margin trend | Stable | Stable |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: BVS fair value analysis · MRK fair value analysis